Last checked at (Sharecast News) - Reneuron Group revealed on Thursday that non-executive director Barbara Staehelin had acquired 43,000 ordinary shares in the AIM-listed cell-based therapeutics developer.
Staehelin, who was appointed as senior independent director at ReNeuron back in July, purchased the shares on Wednesday at an average price of 115.0p each, for a total value of £49,450 each.
Earlier in the week, Reneuron Group said that the first UK subject had been treated at the Oxford Eye Hospital as part of its phase 2a clinical evaluations for the treatment of retinitis pigmentosa (RP) - an inherited, degenerative eye disease.
As of 1640 BST, Reneuron shares were up 0.88% at 115.0p each.
Top Director Buys
Jupiter Fund Management (JUP)
Director name: Formica,Andrew
Amount purchased: 360,413 @ 248.41p
Value: £895,301.97
Reneuron Group (RENE)
Director name: Staehelin,Barbara
Amount purchased: 43,000 @ 115.00p
Value: £49,450.00
Emis Group (EMIS)
Director name: Collis,Denise
Amount purchased: 1,441 @ 1,379.58p
Value: £19,879.75
Golden Prospect Precious Metals Ltd. (GPM)
Director name: Burne,Malcolm Alec
Amount purchased: 25,000 @ 46.00p
Value: £11,500.00
Dialight (DIA)
Director name: Oliver,Karen
Amount purchased: 2,698 @ 367.00p
Value: £9,901.66
Dialight (DIA)
Director name: Haug ,Gotthard
Amount purchased: 2,500 @ 369.75p
Value: £9,243.75
Audioboom Group (BOOM)
Director name: Tobin,Michael
Amount purchased: 140 @ 1,030.00p
Value: £1,442.00
Homeserve (HSV)
Director name: Rusin,Tom
Amount purchased: 20 @ 832.50p
Value: £166.50
Homeserve (HSV)
Director name: Harpin,Richard
Amount purchased: 19 @ 832.50p
Value: £158.17
Homeserve (HSV)
Director name: Bower,David
Amount purchased: 19 @ 832.50p
Value: £158.17
Top Director Sells
Jupiter Fund Management (JUP)
Director name: Formica,Andrew
Amount sold: 360,413 @ 248.40p
Value: £895,265.88
Vertu Motors (VTU)
Director name: Crane,David
Amount sold: 281,916 @ 62.45p
Value: £176,056.54
Vertu Motors (VTU)
Director name: Anderson,Karen
Amount sold: 281,916 @ 62.45p
Value: £176,056.54
Capital Limited (di) (CAPD)
Director name: Abery,David
Amount sold: 17,715 @ 84.00p
Value: £14,880.60
12 Sep 2018 14:44
ReNeuron pleased with progress on several therapy fronts
(Sharecast News) - Cell-based therapeutics developer ReNeuron Group updated the market on its trading on Wednesday, as investors gathered for the firm's annual general meeting, announcing that following recent co-ordinating ethics committee approval, the first clinical site has now been initiated in the US Phase IIb study with its CTX cell therapy candidate for stroke disability.
Read more
